Market Place
Sourcing Support
All News #Library
Biotech
Nouscom Unveils Positive Phase 1/2B Data For NOUS-209 At SITC
07 Nov 2025 //
GLOBENEWSWIRE
Nouscom to Present Ph 1b/2 NOUS-209 Data in Lynch Syndrome
30 Oct 2025 //
GLOBENEWSWIRE
Nouscom Reveals NOUS-209 Immunotherapy Success In MSI-H Cancer
12 Oct 2025 //
GLOBENEWSWIRE
Nouscom’s NOUS-209 Shows Durable Response in Lynch Syndrome
29 Apr 2025 //
GLOBENEWSWIRE
Nouscom To Present Ph Ib/II NOUS-209 Data In Lynch Syndrome At AACR
25 Mar 2025 //
GLOBENEWSWIRE
Nouscom Completes Enrollment of NOUS-209 in dMMR/MSI CRC
19 Nov 2024 //
GLOBENEWSWIRE
Nouscom`s NOUS-209 Shows Potent Immune Responses in Lynch Syndrome
05 Nov 2024 //
GLOBENEWSWIRE
Nouscom To Present NOUS-209 Data In Lynch Syndrome At SITC
04 Oct 2024 //
GLOBENEWSWIRE
Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials
15 Nov 2023 //
ENDPTS
Nouscom™s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential
31 Oct 2023 //
GLOBENEWSWIRE
Nouscom reaches clinical ph II using ProBioGen’s AGE1.CR.pIX production platform
05 May 2023 //
INDIANPHARMAPOST
Nouscom Announces AACR 2023 Presentation of Phase 1b Data of NOUS-PEV
15 Mar 2023 //
GLOBENEWSWIRE
Nouscom Announces Agreement with MSD to Evaluate NOUS-209 with KEYTRUDA
05 Jan 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.